Aug 19, 2019
HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019
May 29, 2019
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer
May 06, 2019
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer
Mar 18, 2019
The global antifungal drugs market size is expected to reach USD 12.7 billion by 2025
Mar 07, 2019
HedgePath Pharmaceuticals Provides Corporate Update for the Fourth Quarter and Year End 2018
Dec 17, 2018
HedgePath Pharmaceuticals and Mayne Pharma Enter into Updated Collaboration and Funding Agreements
Dec 11, 2018
Mayne Pharma receives FDA approval of Tolsura(TM) (SUBA®-itraconazole capsules) for the treatment of certain fungal infections
Nov 21, 2018
Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Oct 09, 2018
HedgePath Pharmaceuticals' Pathway for Filing SUBA BCCNS NDA Clarified in Meeting with FDA
Aug 06, 2018
HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request
Jul 19, 2018
HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
Jul 17, 2018
Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Jul 09, 2018
HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing
Jun 25, 2018
Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Jun 05, 2018
HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
May 21, 2018
HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
May 14, 2018
HedgePath Pharmaceuticals Announces Expanded Patent Coverage
Feb 12, 2018
Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Jan 22, 2018
Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Jan 11, 2018
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs